Third Arc Bio

Third Arc Bio

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.thirdarcbio.com

Last Round

Series A

Extension

Feb 4, 2026

Total Funding Raised

$217M

Company Overview

Third Arc Bio is a biotechnology company focused on developing multifunctional antibodies that deliver transformative therapies for solid tumors, inflammation, and immunological diseases by precisely activating or inhibiting T cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

multifunctional antibodiesantibody therapeuticsimmuno-oncologyT-cell engagersautoimmune disease treatmentimmunology & inflammationI&II&Obispecific antibodiessolid tumor treatmentCD3 T-cell engagersimmune modulationtrispecific antibodiesmasked T-cell engagersclinical-stage biotechT-cell co-stimulationimmune suppressionbiologics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Third Arc Bio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Third Arc Bio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionFeb 4, 2026
Series AJul 23, 2024

Key People

Founding team and executive leadership

Sanjaya Singh

Chief Scientific Officer And Founder

Founding Team

Joseph Erhardt

Chief Operating Officer

Executive Team

Third Arc Bio Investors

Notable investors and investment history

InvestorRounds
Andreessen HorowitzSeries A Extension
Janus Henderson GroupSeries A
Aberdeen GroupSeries A Extension, Series A
Omega FundsSeries A, Seed, Series A Extension
Hillhouse InvestmentSeries A Extension, Series A
abrdn Inc.Series A
Vida VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 4, 2026

    $52M raised in Series A Extension round.

Third Arc Bio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Third Arc Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Third Arc Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range37
Year Founded2022
Last FundingFeb 4, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.